Influence of picumast dihydrochloride on the ex vivo histamine release from leucocytes of allergic asthmatic patients.
In a pilot study 8 patients with allergic obstructive airway disease were treated with the new compound picumast dihydrochloride (3,4-dimethyl-7-[4-(4-chlorobenzyl)piperazine-1-yl]propoxycoumarine++ + dihydrochloride) 2 x 2 mg daily orally during a period of 8 days additionally to a usual therapy of bronchodilators and corticoids in a steady state. It was demonstrated that the compound inhibited the allergen induced histamine liberation of patients basophils significantly. Compared with a collective of patients without an additional picumast dihydrochloride treatment the effect of the substance was shown more clearly. From reasons of these experimental data picumast dihydrochloride may be of a considerable value as a prophylactic agent in allergic bronchial asthma when given orally.
Zimmermann
I
I
Medizinische Universitätsklinik und Poliklinik, Berufsgenossenschaftlichen Krankenanstalten, Bergmannsheil Bochum, Fed. Rep. of Germany.
Roesch
A
A
Ulmer
W T
WT
D001249:Asthma / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D003374:Coumarins / Q000494:pharmacology*; D005260:Female; D006634:Histamine H1 Antagonists / Q000494:pharmacology*; D006636:Histamine Release / Q000187:drug effects*; D006801:Humans; D006967:Hypersensitivity / Q000378:metabolism*; D007962:Leukocytes / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008875:Middle Aged
D003374:Coumarins; D006634:Histamine H1 Antagonists; C013373:picumast